The House that JAK Built: how Pfizer's Xeljanz is poised to take the rheumatoid arthritis crown
This article was originally published in Scrip
Pfizer's new small-molecule Janus kinase inhibitor Xeljanz (tofacitinib) is likely to dominate the rheumatoid arthritis market by the end of the decade, with annual sales in the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) possibly reaching $2.4 billion by 2021, a new report from Datamonitor predicts.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.